1Vik-Mo E O, Nyakas M, Mikkelsen B V, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma[ J]. Cancer Immunol Immunother, 2013, 62(9) : 1499 - 1509.
2Allard S D, De Keersmaecker B, de Goede A L, et al. A phase I/Ila immunotherapy trial of HIV-l-infected patients with Tat, Rev and Nef expressing dendritic cellsfoUowed by treatment interruption[J]. Clin Immunol, 2012, 142(3) : 252 -268.
3Roesle E, Weiss R, WeinbeeT E E, et al. Imratmize and disappear- safety-op'tnnized mRNA vaccination with a panel of 29 allergens [J/OL]. J Allergy Clin Immunol, 2009, 124(5) : 1070 - 1077.doi: 10. 1016/j. jaci. 2009.06. 036. Epub 2009 Aug 8. _ _.
4Gros F, Gilbert W, Hiatt H H, et al. Molecular and biological characterization of messenger RNA [ J ]. Cold Spring Harb Syrup Quant Biol, 1961, 26:111-132.
5Wolff J A, Malone R W, Williams P, et al. Direct gene transfer into mouse muscle in vivo [ J ]. Science, 1990, 247 ( 4949 Pt 1 ) : 1465 - 1468.
6Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA [ J ]. Eur J Immunol, 1993, 23(7): 1719-1722.
7Grudzien-Nogalska E, Kowalska J, Su W, et al. Synthetic mRNAs with superior translation and stability properties [ J ]. Methods Mol Bid, 2013, 969:55 -72.
8Wilgenhof S, Van Nuffel A M, Benteyn D, et al. A phase I B study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients [ J ]. Ann Oncol, 2013, 24(10) : 2686 -2693.
9Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy [ J ]. Cancer Res, 2012, 72(7): 1661 -1671.
10Van Nuffel A M, Benteyn D, Wflgenhof S, et al. Intravenous and intradennal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-Mlc melanoma patient [ J ]. Cancer Immunol Inmaunother, 2012, 61 ( 7 ) : 1033 - 1043.
